Clinical Trials Tracker

What's published, what's pending, and when approval is expected.

A living tracker of every retatrutide clinical trial from Phase 1 through the TRIUMPH Phase 3 program, plus the FDA approval timeline. Updated as new readouts are published.

The program at a glance

Phase	Trial	N	Duration	Status	Headline
1	NCT04143802 (T2D)	—	12 wks	Complete	-8.5 kg; -0.9% HbA1c
2	NCT04881760 (obesity)	338	48 wks	Complete	-24.2% at 12 mg
2	NCT04867785 (T2D)	281	36 wks	Complete	-2.02% HbA1c, -16.94% weight
2	MASLD sub-study	—	—	Complete	81–86% liver fat reduction
3	TRIUMPH-1 (obesity)	~2,300+	72 wks	Active	Pivotal. Readout 2026.
3	TRIUMPH-2 (obesity + T2D)	—	—	Active	Mid-2026
3	TRIUMPH-3 (CV disease)	—	—	Active	2026
3	TRIUMPH-4 (knee OA)	445	68 wks	Complete	-28.7%; 74–76% pain reduction
3	TRIUMPH-5 (CV / renal)	—	Multi-year	Recruiting	MACE endpoints
3b	TRIUMPH-6 (maintenance)	643	—	Active	Closed to new enrollment

Total TRIUMPH Phase 3 enrollment: approximately 5,800 participants. See the full clinical trials deep dive for each trial's design, endpoints, and citations.

2026 readout calendar

Q1–Q2 2026. TRIUMPH-1 and TRIUMPH-2 readouts are the gating events for FDA filing.
H2 2026. TRIUMPH-3 (CV disease) is expected to read out.
2026+. TRIUMPH-5 (CV/renal outcomes) is a multi-year trial; earliest interim reads from 2027+.

How to participate

The primary enrolling trial is TRIUMPH-5 (cardiovascular / renal outcomes). For enrollment process and eligibility:

FDA timeline

The FDA filing trigger is the TRIUMPH-1 primary readout. Eli Lilly's most likely path is a BLA submission in late 2026 or 2027. See the FDA approval timeline article for the full scenario analysis.